Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-066 vs Aranesp in Anemia of CKD on Dialysis
NCT02506868Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Aug 2015
- Primary completion
- Jan 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darbepoetin alfa biosimilar (BCD-066) in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by BIOCAD. Primary endpoint: Change in Hemoglobin Concentration From Baseline to the Evaluation Period at 24 weeks. Started Aug 2015; status: completed.
02
Drugs
darbepoetin alfa biosimilar (BCD-066)
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02506868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506868.